title: Combination chemotherapy with epirubicin and cisplatin in ovarian carcinoma.
abstract: Combination chemotherapy with epirubicin-cisplatin was employed after surgical treatment in 67 women with ovarian carcinoma. 50 mg/m2 of epirubicin and cisplatin each were administered at monthly intervals. The response rate was correlated with the clinical stage and the residual disease. Tumor regression (CR + PR) was observed in 63.6% of patients with stage III disease, and in 50% of those with stage IV disease. Furthermore, complete or partial responses were obtained in 86.4% of patients with a residual deposit of 2-5 cm, and in 33.3% of women with a residual deposit exceeding 5 cm in diameter. Anemia occurred in 47.8%, leukopenia in 43.3%, and thrombocytopenia in 4.5% of the patients. No cardiotoxicity was recorded.
authors.affiliation: Department of Obstetrics and Gynecology, University of Innsbruck, Austria.
authors.forename: L C
authors.initials: LC
authors.lastname: Fuith
authors.forename: A
authors.initials: A
authors.lastname: Bazzanella
authors.forename: H
authors.initials: H
authors.lastname: Hetzel
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage / Q000494:pharmacology; D015251:Epirubicin / Q000008:administration & dosage / Q000494:pharmacology; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D015251:Epirubicin; D002945:Cisplatin